Clostridium Difficile Infections Clostridium Difficile Associated Disease Pipeline Therapeutics Development Review H2 2015

Press Release   •   Dec 08, 2015 06:26 EST

This report provides comprehensive information on the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease) and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Complete report on H2, 2015 Pipeline Review of “Clostridium Difficile Infections” addition with 64 market data tables and 15 figures, spread across 203 pages is .

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from our proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by professional's team. Drug profiles/records featured in the report undergoes periodic updating following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Companies Discussed/Mentioned in this Research:

Absynth Biologics Limited, Actelion Ltd, Adenium Biotech ApS, AIMM Therapeutics B.V., Akthelia pharmaceuticals ehf, AmpliPhi Biosciences Corporation, Angothera GmbH, Assembly Biosciences, Inc., AvidBiotics Corp., C3 Jian, Inc, Daiichi Sankyo Company, Limited, Evec Inc., GangaGen Inc., ImmunoBiology Limited, Immuron Limited, Inovio Pharmaceuticals, Inc., Intrexon Corporation, MedImmune, LLC, Merck & Co., Inc., MGB Biopharma Limited, Microbiotix, Inc., Micropharm Limited, Morphochem AG, Nanotherapeutics, Inc., Novabiotics Limited, NovoBiotic Pharmaceuticals, LLC, Oragenics, Inc., Pfizer Inc., Procarta Biosystems Ltd, Prokarium Limited, Rebiotix Inc., Sanofi Pasteur SA, Sarum Biosciences Limited, Sequella, Inc., Seres Therapeutics, Inc., Shire Plc, Sorrento Therapeutics, Inc., Stellar Biotechnologies, Inc., Summit Therapeutics Plc, Synthetic Biologics, Inc., Valevia UK Limited, Valneva SE and VaxInnate Corporation

Inquire before buying for this report . (This is a premium report price at US$2000 for a single user PDF license)

Drugs Profile Discussed in this Research:

(actoxumab + bezlotoxumab), ABCD-01, actoxumab, AKT-10081, Antibodies for Enterocolitis, AP-114, AvR2-V10, bezlotoxumab, Biologic for Clostridium Difficile Enteropathy, Biologic for Clostridium difficile Infections, C-3CD17, cadazolid, Cdiff snare, clostridium difficile vaccine, CRS-3123, Drug for Clostridium difficile Infection, Endolysin, EV-029104, EV-029105A, fidaxomicin, GBV-006, IMM-529, INS-001, INX-201, MB-101, MBX-500, MCB-3681, MGBBP-3, Monoclonal Antibodies for Clostridium difficile, Monoclonal Antibody for Clostridium Difficile Infections, Monoclonal Antibody to Inhibit Clostridium difficile Toxin A and Toxin B for Clostridium Difficile Infections, MU-1140, NP-432, OraCAb, P-2-A, P-4A, PF-06425090, PolyCAb, PRO-391, ramoplanin, RBX-2660, ridinilazole, SER-109, SER-262, Small Molecule to Inhibit Guanine Riboswitches for MRSA and Clostridium Difficile Infections, Small Molecules for Clostridium Difficile Infections, Small Molecules to Inhibit CD Toxin A and Toxin B for Clostridium Difficile Infections, Small Molecules to Inhibit DNA Synthesis for Infectious Diseases, Small Molecules to Inhibit Dynamin for Clostridium Difficile Infections, SMT-21829, SQ-109, SQ-641, surotomycin, SYN-004, VAL-301, VLA-84 and VP-20621


  • The report provides a snapshot of the global therapeutic landscape of Clostridium Difficile Infections (Clostridium Difficile Associated Disease)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Clostridium Difficile Infections (Clostridium Difficile Associated Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Clostridium Difficile Infections (Clostridium Difficile Associated Disease) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy:

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Clostridium Difficile Infections (Clostridium Difficile Associated Disease) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Explore More Research Report on Infectious Diseases Therapeutics Market. is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries